NIAID HERA Clinical Trial Reveals CMV Reactivation in ART-Treated HIV Women with Low CD4
Clinical Results
The HERA study NCT03092505, supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), is a completed non-interventional study evaluating herpesvirus reactivation in HIV-infected women initiating antiretroviral therapy (ART). Conducted from June 2018 to February 2021 at the NIH Clinical Center in the U.S. and Rakai District in Uganda, 187 of 196 eligible participants were enrolled. In the overall cohort, no significant changes in the shedding rates of cytomegalovirus (CMV), herpes simplex virus (HSV)-1/2, varicella-zoster virus (VZV), and Kaposi’s sarcoma-associated herpesvirus (KSHV) were observed at 4 and 8 weeks post-treatment. This does not support the interpretation that ART universally induces herpes reactivation in all patients.
High-Risk Group Signal
Among women with baseline CD4 T-cell counts ≤200 cells/µL, cervical/vaginal CMV shedding increased from 50% pre-ART to 76% at 4 weeks and 74% at 8 weeks, with p-values of 0.016 and 0.027, respectively. In contrast, the group with CD4 >200 cells/µL remained stable at 42%, 41%, and 41%. At 24 weeks, 96% of participants had HIV-1 plasma viral loads suppressed below detectable levels, and 74% showed CD4 increases of more than 50 cells/µL. This suggests that, independent of ART’s antiretroviral efficacy, close monitoring for early CMV mucosal reactivation is necessary in patients with severe immunosuppression.
Drug and Competitive Landscape
The trial did not compare specific new drugs but provided standard-of-care ART and opportunistic infection treatment. The current representative HIV-1 complete regimen includes Gilead Sciences (GILD)'s Biktarvy, a combination of bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir inhibits HIV-1 integrase strand transfer, while emtricitabine and tenofovir inhibit reverse transcriptase. It was FDA-approved on February 7, 2018, for adult HIV-1 treatment. The competitive standard-of-care, ViiV Healthcare’s Dovato, consists of dolutegravir and lamivudine, targeting integrase and reverse transcriptase, and received FDA approval on April 8, 2019. For herpes-related diseases, acyclovir and valacyclovir are standard antivirals for HSV and VZV, while valganciclovir and ganciclovir are used for CMV end-organ disease.
Market and Industry Implications
The global HIV treatment market is projected to grow from USD 10.3 billion in 2022 to USD 11.3 billion in 2030, with North America accounting for 51.5% of 2022 revenue. HERA is not a comparative efficacy study for ART switching but a biomarker study focused on early risk-stratification using CD4 levels and CMV shedding. Baseline CRP, TNF-α, and TNFR1 are also associated with post-treatment CMV shedding, offering a starting point for immune-inflammatory-based patient stratification. However, due to its design centered on enrolled women and Ugandan data, its commercial value lies more in infection monitoring, companion diagnostics, and CMV-targeted interventional trial design rather than new prescription expansion.
The completed non-interventional HERA study with 187 participants revealed a clinically distinct risk signal: CMV shedding increased from 50% to 76% at 4 weeks in women with baseline CD4 ≤200 cells/µL. For researchers, this provides a rationale for patient stratification combining CD4 with CRP, TNF-α, and TNFR1, as well as preventive CMV interventional trials. For the industry, it offers a differentiator beyond the competitive viral suppression of marketed ARTs like Biktarvy and Dovato by providing data on opportunistic infection management. While it does not provide comparative efficacy data to change short-term HIV treatment guidelines, the concurrent 96% viral suppression at 24 weeks and mucosal CMV reactivation in the first 4–8 weeks reinforce the need for early monitoring. In the medium to long term, follow-up randomized clinical trials validating the investment case for diagnostics, monitoring, and CMV combination strategies will be key value drivers in the USD 11.3 billion HIV treatment market projected for 2030.
Source: ClinicalTrials.gov (api_ct)